As of 2026-03-15, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (5.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.26 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -217.8%.
The range of the Relative Valuation is (4.75) - (5.06) USD.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| Trailing P/E multiples | 21.1x - 25.6x | 23.4x |
| Forward P/E multiples | 21.6x - 23.0x | 22.3x |
| Fair Price | (4.75) - (5.06) | (5.02) |
| Upside | -211.5% - -218.7% | -217.8% |
| Date | P/E |